FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322496507> ?p ?o ?g. }

• W4322496507 endingPage "706" @default.
• W4322496507 startingPage "693" @default.
• W4322496507 abstract "There is a paucity of data on how patient characteristics may affect the long-term durability of certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA). This study therefore aimed to investigate CZP durability and reasons for discontinuation over 5 years between different subgroups of patients with RA.Data were pooled from 27 clinical trials in RA patients. Durability was defined as the percentage of patients randomized to CZP at baseline who were still on CZP treatment at a given timepoint. Post hoc analyses of clinical trial data on CZP durability and reasons for discontinuation among different patient subgroups were conducted using Kaplan-Meier curves and Cox proportional hazards modeling. Patient subgroups included: age (18- < 45/45- < 65/ ≥ 65 years), gender (male/female), prior tumor necrosis factor inhibitor (TNFi) use (yes/no), and disease duration (< 1/1- < 5/5- < 10/ ≥ 10 years).Among 6927 patients, the durability of CZP was 39.7% at 5 years. Patients aged ≥ 65 years had a 33% greater risk of CZP discontinuation than patients 18- < 45 years (hazard ratio [95% confidence interval]: 1.33 [1.19-1.49]) and patients with prior TNFi use had a 24% greater risk of discontinuing CZP than patients without (1.24 [1.12-1.37]). Conversely, greater durability was observed among patients who had a baseline disease duration of ≥ 1 year. Durability did not differ in the gender subgroup. Of the 6927 patients, the most common reason for discontinuation was inadequate levels of efficacy (13.5%); followed by adverse events (11.9%); consent withdrawn (6.7%); lost to follow-up (1.8%); protocol violation (1.7%); other reasons (9.3%).CZP durability was comparable with durability data on other bDMARDs in RA patients. Patient characteristics that were associated with greater durability included younger age, TNFi-naïvety, and disease duration ≥ 1 year. Findings may be helpful in informing clinicians on a patient's likelihood of discontinuing CZP, based on their baseline characteristics." @default.
• W4322496507 created "2023-02-28" @default.
• W4322496507 creator A5004270076 @default.
• W4322496507 creator A5006070255 @default.
• W4322496507 creator A5011826741 @default.
• W4322496507 creator A5015953107 @default.
• W4322496507 creator A5045325872 @default.
• W4322496507 creator A5075502252 @default.
• W4322496507 creator A5075921624 @default.
• W4322496507 creator A5080692753 @default.
• W4322496507 date "2023-02-27" @default.
• W4322496507 modified "2023-09-25" @default.
• W4322496507 title "Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data" @default.
• W4322496507 cites W1511861289 @default.
• W4322496507 cites W1561772993 @default.
• W4322496507 cites W1674780110 @default.
• W4322496507 cites W1753406942 @default.
• W4322496507 cites W2000248833 @default.
• W4322496507 cites W2006566716 @default.
• W4322496507 cites W2031494385 @default.
• W4322496507 cites W2079590652 @default.
• W4322496507 cites W2091055562 @default.
• W4322496507 cites W2095439262 @default.
• W4322496507 cites W2103270747 @default.
• W4322496507 cites W2106962952 @default.
• W4322496507 cites W2109655434 @default.
• W4322496507 cites W2112543361 @default.
• W4322496507 cites W2120393706 @default.
• W4322496507 cites W2124227426 @default.
• W4322496507 cites W2139201413 @default.
• W4322496507 cites W2153124348 @default.
• W4322496507 cites W2163817180 @default.
• W4322496507 cites W2206432491 @default.
• W4322496507 cites W2262742107 @default.
• W4322496507 cites W2342776269 @default.
• W4322496507 cites W2345425230 @default.
• W4322496507 cites W2345809227 @default.
• W4322496507 cites W2410520654 @default.
• W4322496507 cites W2492966777 @default.
• W4322496507 cites W2549844032 @default.
• W4322496507 cites W2747229477 @default.
• W4322496507 cites W2772318288 @default.
• W4322496507 cites W2791681362 @default.
• W4322496507 cites W2803973097 @default.
• W4322496507 cites W2895180416 @default.
• W4322496507 cites W2947169332 @default.
• W4322496507 cites W2949517113 @default.
• W4322496507 cites W2973343851 @default.
• W4322496507 cites W3021873102 @default.
• W4322496507 cites W3033769681 @default.
• W4322496507 cites W3033984526 @default.
• W4322496507 cites W3171954900 @default.
• W4322496507 cites W3175691538 @default.
• W4322496507 cites W4211111012 @default.
• W4322496507 cites W4231972505 @default.
• W4322496507 cites W4232642069 @default.
• W4322496507 doi "https://doi.org/10.1007/s40744-023-00541-5" @default.
• W4322496507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36848009" @default.
• W4322496507 hasPublicationYear "2023" @default.
• W4322496507 type Work @default.
• W4322496507 citedByCount "0" @default.
• W4322496507 crossrefType "journal-article" @default.
• W4322496507 hasAuthorship W4322496507A5004270076 @default.
• W4322496507 hasAuthorship W4322496507A5006070255 @default.
• W4322496507 hasAuthorship W4322496507A5011826741 @default.
• W4322496507 hasAuthorship W4322496507A5015953107 @default.
• W4322496507 hasAuthorship W4322496507A5045325872 @default.
• W4322496507 hasAuthorship W4322496507A5075502252 @default.
• W4322496507 hasAuthorship W4322496507A5075921624 @default.
• W4322496507 hasAuthorship W4322496507A5080692753 @default.
• W4322496507 hasBestOaLocation W43224965071 @default.
• W4322496507 hasConcept C126322002 @default.
• W4322496507 hasConcept C207103383 @default.
• W4322496507 hasConcept C2776215756 @default.
• W4322496507 hasConcept C2777226972 @default.
• W4322496507 hasConcept C2777575956 @default.
• W4322496507 hasConcept C2778715236 @default.
• W4322496507 hasConcept C44249647 @default.
• W4322496507 hasConcept C71924100 @default.
• W4322496507 hasConceptScore W4322496507C126322002 @default.
• W4322496507 hasConceptScore W4322496507C207103383 @default.
• W4322496507 hasConceptScore W4322496507C2776215756 @default.
• W4322496507 hasConceptScore W4322496507C2777226972 @default.
• W4322496507 hasConceptScore W4322496507C2777575956 @default.
• W4322496507 hasConceptScore W4322496507C2778715236 @default.
• W4322496507 hasConceptScore W4322496507C44249647 @default.
• W4322496507 hasConceptScore W4322496507C71924100 @default.
• W4322496507 hasFunder F4320337846 @default.
• W4322496507 hasIssue "3" @default.
• W4322496507 hasLocation W43224965071 @default.
• W4322496507 hasLocation W43224965072 @default.
• W4322496507 hasLocation W43224965073 @default.
• W4322496507 hasOpenAccess W4322496507 @default.
• W4322496507 hasPrimaryLocation W43224965071 @default.
• W4322496507 hasRelatedWork W2045151582 @default.
• W4322496507 hasRelatedWork W2082406232 @default.
• W4322496507 hasRelatedWork W2156283049 @default.
• W4322496507 hasRelatedWork W2316954211 @default.

• next